This inventor holds 1 USPTO granted patent. Top assignee: Van Andel Research Institute. Active years: 2020.
Company Filing History:
Years Active: 2020
Title: Innovations by Bryan Reatini in Cancer Diagnosis
Introduction
Bryan Reatini is an accomplished inventor based in Grand Rapids, MI (US). He has made significant contributions to the field of medical diagnostics, particularly in the detection of pancreatic cancer. His innovative approach focuses on the detection of specific glycoforms, which can play a crucial role in diagnosing this challenging disease.
Latest Patents
Bryan Reatini holds a patent for a method of detecting the level of a glycan. This method involves diagnosing pancreatic cancer by detecting the levels of one or more glycoforms of a Lewis antigen and MUC5AC. The process allows for the identification of patients diagnosed with pancreatic cancer, enabling timely treatment. The patent outlines a method for detecting glycan levels in a sample, which includes using a capture reagent to immobilize the glycan on a substrate, exposing it to a detection reagent, and combining the biological sample with pre-capture and pre-detection enzymes. He has 1 patent to his name.
Career Highlights
Bryan Reatini is affiliated with the Van Andel Research Institute, where he continues to advance research in cancer diagnostics. His work is characterized by a commitment to improving patient outcomes through innovative diagnostic methods.
Collaborations
One of his notable collaborators is Brian Brummeler Haab, with whom he has worked on various research projects aimed at enhancing cancer detection techniques.
Conclusion
Bryan Reatini's contributions to the field of cancer diagnostics exemplify the impact of innovative thinking in medicine. His patented methods for detecting glycan levels represent a significant advancement in the early diagnosis of pancreatic cancer.